Abstract: A dialysis system includes: (i) a source of water made suitable for a dialysis treatment; (ii) at least one concentrate for mixing with the water from the source; (iii) a dialysis fluid pump; and (iv) a disposable set operable with the dialysis fluid pump and in fluid communication with the source of water and the at least one concentrate, the disposable set including a container having a first end and a second end, the container configured to allow the water and the at least one concentrate pumped by the dialysis fluid pump to enter at the second end and exit from the first end to mix for the dialysis treatment.

Abstract: The present disclosure relates to a hemodialysis membrane for the treatment of vascular calcification in hemodialysis patients, especially in chronic hemodialysis patients. The present disclosure further relates to methods of treating vascular calcification in hemodialysis patients, wherein the hemodialysis membrane is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD or that the hemodialysis membrane comprises at least one hydrophobic polymer and at least one hydrophilic polymer and has a MWRO of between 8.5 kD and 14.0 kD and a MWCO of between 55 kD and 130 kD.

Abstract: An extracorporeal blood treatment apparatus is provided comprising a filtration unit (2) connected to a blood circuit (17) and to a dialysis fluid circuit (32), a preparation device (9) for preparing and regulating the composition of the dialysis fluid; a control unit (12) is configured for determining or receiving a proposed value (Condprop) of a conductivity for the dialysis fluid in the dialysis supply line (8) and to determine a set value (Condset) for the conductivity in the dialysis fluid as a function of the proposed value (Condprop) and as a function of at least one of a second parameter (UF volume/W; WL/W) indicative of a patient fluid overload and a third parameter (gconc) chosen in the group including: a glucose concentration in the patient and a concentration-related parameter of at least glucose in the patient.

Abstract: A monitoring system (9) performs a method for detecting a disruption of a fluid connection between a first fluid containing system and a second fluid containing system. The monitoring system generates a monitoring signal (M1) which is representative of a fluid pressure in respect of the first fluid containing system and which is responsive to the disruption of the fluid connection, and a tracking signal (T1) which corresponds to and is more smoothed over time than the monitoring signal (M1). The monitoring system (9) further sets a detection range (M1L, M1H) in a given relation to the tracking signal (T1) so that the detection range (M1L, M1H) follows changes in the tracking signal (T1), and detects a condition indicative of the disruption by comparing a current pressure value of the monitoring signal (M1) to the detection range (M1L, M1H).

Abstract: A renal failure therapy system (10a, 10b) includes a dialysis fluid circuit (30) including a dialysis fluid pump (54, 58); a source (86, 90) of physiological cleaning, disinfecting, and/or decalcifying substance in fluid communication with the dialysis fluid circuit; a source (22) of purified water in fluid communication with the dialysis fluid circuit; and a logic implementer (20) in operable communication with the dialysis fluid pump (54,58), the logic implementer (20) causing the physiological cleaning, disinfecting, and/or decalcifying substance from its source (86, 90) to be added to purified water from the purified water source (22) to form a mixture and to circulate the mixture within the dialysis fluid circuit using the dialysis fluid pump (54,58) to at least one of clean, disinfect or decalcify at least a portion of the dialysis fluid circuit (30) without a subsequent rinse.

Abstract: A tube for a peristaltic pump comprises an elastically deformable tubular body (2) made from a PVC composition containing: 100 phr of a PVC resin having a K value, measured according to standard ISO 1628-2, of not less than 85, from 40 to 100 phr of DEHA plasticizer, from 0.05 to 1.0 phr of lubricant, from 0.3 to 15.0 phr of stabilizer and co-stabilizer. The deformable tube, which is usefully employed for liquid transport in a dialysis apparatus, enables a high level of fluid transport efficiency to be maintained, even after many hours of peristaltic pump operation.

Abstract: A monitoring device implements a monitoring method that comprises: activating a first monitoring technique that operates to detect the disruption and generate a corresponding alarm signal while a second monitoring technique is deactivated, obtaining at least one of a first count of false alarms generated by the primary monitoring technique and a second count of false alarms generated by the second monitoring technique if activated, and selectively, based on at least one of the first and second counts, activating the second monitoring technique to operate, instead of or jointly with the first monitoring technique, to detect the disruption and generate the corresponding alarm signal. The monitoring device may be connected to or part of an apparatus for blood treatment and operable to detect a disconnection of an extracorporeal blood circuit from a vascular system of a patient, e.g. a venous-side disconnection.

Abstract: A male fluid connector, a female fluid connector, and a connection system comprising the connectors. The connection system comprises a male connector and a female connector that both are modified such that they cannot be engaged. The connection system removes the risk of unintentional connection of the two modified connectors not intended to be connected but still allows connection of the two modified connectors to other non-modified connectors.

Abstract: A peritoneal dialysis system includes a water purifier, a cycler, and a disposable set operable with the cycler. The disposable set includes a pumping cassette including a water inlet port, a heater/mixing container in fluid communication with the pumping cassette, a water accumulator, a first water line segment, and a second water line segment. The first water line segment is in fluid communication with the water inlet port and the water accumulator. Additionally, the second water line segment is in fluid communication with the water accumulator and the water purifier.

Abstract: The present invention concerns an anticoagulation fluid comprising 10-40 mM citrate and 0.1-4 mM phosphate. The anticoagulation fluid is to be used for regional citrate anticoagulation in an extracorporeal blood circuit. The anticoagulation fluid may be combined with at least one treatment fluid in a dialysis treatment, and it may be included in a system for regional citrate anticoagulation in an extracorporeal blood circuit.

Abstract: An apparatus for extracorporeal blood treatment comprises a sensor (10) for emitting a signal indicating a variation in blood volume (?Bv?) of an individual (7) subjected to extracorporeal blood treatment and a sensor (14) for emitting a signal indicating a weight loss of the individual. A control unit (20) receives the signals, compares the ratio between the relative variation of blood volume (?Bv/BV) and the relative variation of weight loss (AWL/TW) of the individual with a desired value, and controls the weight loss of the individual on the basis of the comparison. The apparatus enables automatically controlling a dialysis, preventing some complications due to hypotension.

Abstract: Blood treatment apparatus and methods of using the same are described herein that include two or more intermediate containers located between a treatment solution source and a port through which the treatment solution is to be delivered with the blood treatment apparatus. The weight of the intermediate containers is measured and used to control the refilling and emptying of treatment solution in the intermediate containers.

Abstract: It is described an extracorporeal blood treatment apparatus (1) with a user interface (12) device capable configuring and allowing execution of one or more isolated ultrafiltration tasks during the course of a dialysis treatment. The extracorporeal blood treatment apparatus (1) is controlled in a normal mode, where dialysis fluid is fed to the blood treatment unit (2), and in an isolated ultrafiltration mode, where fresh dialysis fluid is no longer fed to the blood treatment unit (2).

Abstract: A blood treatment apparatus is disclosed. In an example, the blood treatment apparatus includes a blood treatment unit; a blood line configured to extract blood from a blood source, pass the blood through the blood treatment unit and deliver treated blood to a target vessel; and a fluid line configured to pass treatment fluid through the blood treatment unit and deliver used treatment fluid to a fluid sink. A flow divider is arranged in the fluid line for separating treatment fluid into to a first fluid section and a second fluid section, thereby electrically isolating the fluid sections such that electrical current flowing in the fluid line between the fluid sections is limited. Related manufacturing and verification methods are also described.

Abstract: The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consist of powder components comprising sodium chloride, at least one dry acid and at least one magnesium salt, and optionally potassium salt, calcium salt, and glucose. According to the invention said at least one magnesium salt and said optional glucose, are present as anhydrous components in said dialysis acid precursor composition.

Abstract: A normal workflow including a plurality of steps may be defined by exemplary systems and methods for use in preparing a treatment, performing a treatment, and performing post-treatment processes. A user may be guided by one or more workflow affordances to indicate where and how to use a graphical user interface to follow the normal workflow. When a user deviates from the normal workflow, one or more deviation workflow affordances may be displayed on the graphical user interface to guide a user back to the normal workflow.

Abstract: A monitoring device is included in a medical system to implement a method for prediction of a rapid symptomatic drop in a subject's blood pressure, e.g. during a medical treatment such as dialysis. To this aim, a pulse shape parameter (pPS) with respect to a pulse generator of the subject is registered by means of a pressure sensor arranged in an extracorporeal blood flow circuit coupled to a cardiovascular system of the subject (P). The pressure sensor is configured to detect pressure variations in blood vessels of the subject (P). It is investigated, during measurement period, whether or not one or more of the pulse shape parameters fulfil a decision criterion. An output signal (a) is generated if the decision criterion is found to be fulfilled, to indicate a predicted rapid symptomatic blood pressure decrease in the subject (P).

Abstract: Graphical user interfaces for use with extracorporeal blood treatment systems may include one or more bar-type parameter adjustment elements. The bar-type parameter adjustment elements may be used to ascertain and adjust one or more parameters related to one or more processes performed by the extracorporeal blood treatment systems. The bar-type parameter adjustment element may be scaled such that midpoint of the bar-type parameter adjustment element is representative of a reference value.

Abstract: A membrane for cultivating adherent or suspension cells, in particular adherent cells. The membrane permits adhesion and proliferation of the cells due to the irradiation of the wet or dry membrane with gamma or beta rays or an electron beam in a dose of from 12.5 to 175 kGy in the presence of oxygen. The resulting membrane may be used without any pre-treatment with surface-modifying substances. A method for preparing such an irradiated membrane for cultivating adherent or suspension cells. Methods of using such a membrane for cultivating adherent or suspension cells.

Abstract: The present disclosure relates to improved semipermeable membranes based on acrylonitrile copolymers for use in dialyzers for the extracorporeal treatment of blood in conjunction with hemodialysis, hemofiltration or hemodiafiltration. The present disclosure further relates to methods of producing such membranes.